PBM Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.600

Open

2.500

VWAP

2.53

Vol

29.36K

Mkt Cap

2.88M

Low

2.470

Amount

74.19K

EV/EBITDA(TTM)

--

Total Shares

1.15M

EV

-1.29M

EV/OCF(TTM)

--

P/S(TTM)

--

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Show More

Events Timeline

(ET)

2026-03-03

09:20:00

Psyence Biomedical Exports NPX-5 Product to Australia

2026-02-17 (ET)

2026-02-17

09:30:00

Psyence Biomedical Announces Voting Results from Annual Shareholders Meeting

2026-02-13 (ET)

2026-02-13

18:40:00

Psyence Biomedical Enters Put Option Agreement with PsyLabs

2026-02-11 (ET)

2026-02-11

09:20:00

Psyence Biomedical Reaches Settlement Agreement with KAOS Capital

News

Newsfilter

03-03Newsfilter

Psyence BioMed Successfully Exports GMP-Compliant Psychedelic Product

Benzinga

Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading

Newsfilter

02-20Newsfilter

Psyence BioMed Exercises Put Option to Invest in PsyLabs

Newsfilter

02-17Newsfilter

Psyence BioMed Announces Shareholder Meeting Voting Results

Newsfilter

02-13Newsfilter

Psyence BioMed Enters Put Option Agreement with PsyLabs

Newsfilter

02-11Newsfilter

Psyence Biomedical Settles Shareholder Claim for $1.5 Million

Valuation Metrics

The current forward P/E ratio for Psyence Biomedical Ltd (PBM.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Psyence Biomedical Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks under $1 that fell 5% or more

Intellectia · 66 candidates

Price: <= $1.00Price Change Pct: <= $-5.00

Ticker

Name

Market Cap$

Psyence Biomedical Ltd

890.11K

IO Biotech Inc

14.94M

Innovation Beverage Group Ltd

3.33M

Jeffs Brands Ltd

2.33M

Super League Enterprise Inc

5.88M

Skycorp Solar Group Ltd

11.55M

stocks under $2 that fell 5% or more

Intellectia · 109 candidates

Price: <= $2.00Price Change Pct: <= $-5.00

Ticker

Name

Market Cap$

Psyence Biomedical Ltd

890.11K

IO Biotech Inc

14.94M

Venus Concept Inc

3.51M

Innovation Beverage Group Ltd

3.33M

Jeffs Brands Ltd

2.33M

Surgepays Inc

25.72M

find stocks under $2 that fell 5% or more

Intellectia · 109 candidates

Price: <= $2.00Price Change Pct: <= $-5.00

Ticker

Name

Market Cap$

Psyence Biomedical Ltd

890.11K

IO Biotech Inc

14.94M

Venus Concept Inc

3.51M

Innovation Beverage Group Ltd

3.33M

Jeffs Brands Ltd

2.33M

Surgepays Inc

25.72M

stocks with an rsi under 5

Intellectia · 221 candidates

Rsi Category: oversold

Ticker

Name

Market Cap$

Psyence Biomedical Ltd

890.11K

IO Biotech Inc

14.94M

Innovation Beverage Group Ltd

3.33M

Surgepays Inc

25.72M

Four Seasons Education (Cayman) Inc

17.36M

J-Long Group Ltd

13.50M

with an rsi under 10

Intellectia · 221 candidates

Rsi Category: oversold

Ticker

Name

Market Cap$

Psyence Biomedical Ltd

890.11K

IO Biotech Inc

14.94M

Innovation Beverage Group Ltd

3.33M

Surgepays Inc

25.72M

Four Seasons Education (Cayman) Inc

17.36M

J-Long Group Ltd

13.50M

stocks that fell over 20% yesterday

Intellectia · 19 candidates

Price Change Pct: $-100.00 - $-20.00

Ticker

Name

Market Cap$

Psyence Biomedical Ltd

890.11K

IO Biotech Inc

14.94M

Venus Concept Inc

3.51M

Innovation Beverage Group Ltd

3.33M

Jeffs Brands Ltd

2.33M

Surgepays Inc

25.72M

stock to buy low and sell high today

Intellectia · 10 candidates

Relative Vol: >= 2Pe Ttm: <= 15Rsi 14: <= 25Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-3.00

Ticker

Name

Market Cap$

Diginex Ltd

292.33M

Net Lease Office Properties

279.84M

iHuman Inc

92.42M

IO Biotech Inc

14.94M

J-Long Group Ltd

13.50M

Future Fintech Group Inc

10.55M

Whales Holding PBM

Trading Trends

People Also Watch

Frequently Asked Questions

What is Psyence Biomedical Ltd (PBM) stock price today?

The current price of PBM is 2.51 USD — it has decreased -1.57

What is Psyence Biomedical Ltd (PBM)'s business?

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

What is the price predicton of PBM Stock?

Wall Street analysts forecast PBM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Psyence Biomedical Ltd (PBM)'s revenue for the last quarter?

Psyence Biomedical Ltd revenue for the last quarter amounts to -1.51M USD, increased 30.18

What is Psyence Biomedical Ltd (PBM)'s earnings per share (EPS) for the last quarter?

Psyence Biomedical Ltd. EPS for the last quarter amounts to -251456.00 USD, decreased

How many employees does Psyence Biomedical Ltd (PBM). have?

Psyence Biomedical Ltd (PBM) has 12 emplpoyees as of March 11 2026.

What is Psyence Biomedical Ltd (PBM) market cap?

Today PBM has the market capitalization of 2.88M USD.